The numbers are clear: 160 million adults in the U.S. want to improve their health and well-being through weight loss. As many employers already know, adding obesity management programs to health benefit plans can boost employee motivation and health outcomes. For those who are affected, reducing weight by just 5-10% can improve risk factors and reduce medical complications. These targeted programs also acknowledge that obesity is a complex, chronic disease and it deserves dedicated and comprehensive care.<\/p>\n\n\n\n
Early trials have suggested GLP-1s are the most effective anti-obesity medications the medical community has ever had: Studies have shown<\/a> that weight losses of up to 10-15% are possible. With last year\u2019s approval<\/a> of tirzepatide for obesity, the combined power of a GLP-1 with another gut hormone enhancer (GIP) has shown even more promise with losses of up to an astounding 48 pounds or 21% of body weight at 88 weeks vs. placebo in one study. As a result, GLP-1 demand has skyrocketed, with half of U.S. adults<\/a> who have heard of these weight loss medications interested in trying them. And as GLP-1s are proving beneficial in other disorders including cardiovascular disease, demand is likely to continue to increase.<\/p>\n\n\n\n GLP-1s are an important new tool for weight loss\u2013but as with any tool, they have their limitations. Even with their power, it is clear that medication alone is not enough: When people stop taking the medication, studies show<\/a> the weight comes back.<\/p>\n\n\n\n To help reduce the setbacks so many people encounter on GLP-1s, and to ensure your employees are set up for weight management success, any obesity management program offered to your employees should include a comprehensive approach that includes pairing medication with substantial, long-lasting lifestyle changes. The cornerstones of healthy behaviors like nutrition, exercise, stress management, and sleep are all essential to achieve outcomes. Drugs alone can\u2019t rewire the brain\u2019s craving pathways, or fix insulin resistance. For GLP-1s and other anti-obesity medications to be most effective, it is abundantly clear that they need to be part of a personalized program that reflects the person\u2019s unique biology, lifestyle, and importantly, personal preferences for ongoing engagement and motivation.<\/p>\n\n\n\n Noom Med<\/a> is our way of delivering on this mandate\u2014it is our cutting-edge obesity treatment program that combines clinical care and medications with psychology-based behavior change, integrating evidence-based obesity medicine, specially trained clinicians, and our award-winning app that has been proven to work for millions of people.<\/p>\n\n\n\n GLP-1s are a novel class of pharmaceuticals that demand a specialized companion app. The reason why is so easy to see: current data suggest that many if not most people currently taking a GLP-1 will not be on it forever. <\/p>\n\n\n\n At Noom, we know that many employees will receive GLP-1s and other anti-obesity medications through their doctor or another source. We have a rich history<\/a> in providing companion app support to users facing serious health issues: Long before Noom Med existed, we partnered with Novo Nordisk to provide companion app support for Saxenda users, with impressive results. We were also the first CDC-approved app-based Diabetes Prevention Program<\/a>, which has helped many reduce their risk factors for diabetes and related comorbidities.<\/p>\n\n\n\n Noom\u2019s ability to create lasting lifestyle changes along with metabolic health improvements has been shown in over 50 published peer-reviewed studies. In fact, one study showed that Noom combined with an early GLP-1 produced far better weight loss outcomes than the GLP-1 alone. This was surprising and unusual, as in general the lifestyle arm of anti-obesity medication trials vastly underperforms the drug. <\/p>\n\n\n\n More weight loss reported<\/p>[\/et_pb_text][et_pb_image src=”https:\/\/assets.noom.com\/uploads\/2024\/04\/noom-glp-1-users-graph.png” title_text=”Noom + GLP-1 Users Graph” _builder_version=”4.24.3″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”1_3″ module_class=”glp1-column” _builder_version=”4.24.3″ _module_preset=”default” custom_padding=”|25px||25px|false|true” border_width_right=”2px” border_color_right=”#FFFFFF” global_colors_info=”{}”][et_pb_text _builder_version=”4.24.3″ _module_preset=”default” header_text_align=”center” header_3_font=”|700||on|||||” header_3_font_size=”20px” text_orientation=”center” global_colors_info=”{}”] Noom + GLP users were 1.6x more likely to discontinue their early stage GLP-1 prescription.<\/p>[\/et_pb_text][et_pb_code admin_label=”Custom CSS” _builder_version=”4.24.3″ _module_preset=”default” global_colors_info=”{}”]The Challenge<\/h2>\n\n\n\n
Noom\u2019s Edge as a Companion App<\/h2>\n\n\n\n
Our behavior change model has proven to amplify and even outperform<\/em> early stage GLP-1s.<\/h2>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ use_custom_gutter=”on” gutter_width=”1″ make_equal=”on” module_id=”glp1-graphic” _builder_version=”4.24.3″ _module_preset=”default” width=”100%” custom_css_free_form=”||#glp1-graphic h3 {font-family: %22BrownLLWeb%22;}||#glp1-graphic .stat {font-family: ‘Untitled Serif’;}” global_colors_info=”{}”][et_pb_column type=”1_3″ module_class=”glp1-column” _builder_version=”4.24.3″ _module_preset=”default” custom_padding=”|25px||25px|false|true” border_color_all=”#191717″ border_width_right=”2px” border_color_right=”#FFFFFF” global_colors_info=”{}”][et_pb_text _builder_version=”4.24.3″ _module_preset=”default” header_text_align=”center” header_3_font=”|700||on|||||” header_3_font_size=”20px” text_orientation=”center” global_colors_info=”{}”]
BETTER HEALTH OUTCOMES<\/h3>[\/et_pb_text][et_pb_text _builder_version=”4.24.3″ _module_preset=”default” header_text_align=”center” header_3_font=”|700||on|||||” header_3_font_size=”20px” text_orientation=”center” custom_margin=”15px||15px||true|false” global_colors_info=”{}”]
LESS GLP-1 UTILIZATION<\/h3>[\/et_pb_text][et_pb_text _builder_version=”4.24.3″ _module_preset=”default” header_text_align=”center” header_3_font=”|700||on|||||” header_3_font_size=”20px” text_orientation=”center” custom_margin=”25px||||false|false” global_colors_info=”{}”]
\n